<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938012</url>
  </required_header>
  <id_info>
    <org_study_id>2017/00640</org_study_id>
    <nct_id>NCT03938012</nct_id>
  </id_info>
  <brief_title>Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma</brief_title>
  <official_title>Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focuses on advanced lung and head and neck SCC tumours, with adjacent normal lung
      tissues. Biopsies will be performed in National University Health System, Singapore (NUHS) as
      part of participants' standard care. Patient blood was also required for extraction of cell
      free DNA (cfDNA) and genomic DNA (gDNA). Patients' medical records will also be reviewed for
      the purpose of this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:

      To investigate the prevalence of MET and TP53 mutations, as well as HER2 and MET
      amplification, in lung and head and neck tumours, through prospective collection of tumour
      specimens in newly recruited patients.

      Secondary objectives:

        1. To distinguish the presence of somatic/germline MET and TP53 mutation in lung and head
           and neck tumours.

        2. To detect for amplifications of MET and/or HER2 genes in SCC samples.

        3. To investigate the association and interaction of cMet and HER2 in SCC tumours.

        4. To establish a prospective documation of clinical, histopathological, treatment and
           follow-up (clinic pathological) data of newly recruited patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 3, 2017</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of MET mutation using digital droplet PCR (ddPCR)</measure>
    <time_frame>2 years</time_frame>
    <description>Germline DNA from the patients will be harvested from whole blood, and the polymorphic MET variant will be determined using ddPCR. Customised probes detecting wildtype MET allele or MET-N375S allele are designed to for genotyping (homozygous/heterozygous).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of TP53 mutation using Sanger sequencing</measure>
    <time_frame>2 years</time_frame>
    <description>DNA from the tumour specimens will be harvested for sequencing to identify cases with somatic mutations of TP53 gene. Changes in codon sequences will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of MET and HER2 amplification using fluorescence in situ hybridization (FISH)</measure>
    <time_frame>2 years</time_frame>
    <description>FFPE samples retrieved from patients genotyped with MET-N375S polymorphism will be subjected to MET and HER2 testing Abbott PathVysion DNA test kits. Data will be analysed with fluorescence microscopy. HER2 amplification will be defined as gene copies versus chromosome 17 polysomy. MET amplification will be defined as gene copies per nucleus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interaction of MET and HER2 receptor tyrosine kinases using proximity ligation assay (PLA)</measure>
    <time_frame>2 years</time_frame>
    <description>PLA will be performed using DUOLINK in situ hybridization. Validation MET and HER2 antibodies will be used for the assay, and signal will be detected with fluorescence microscopy. Detection and quantification of positive signals will determine the presence of MET-HER2 interaction in clinical specimens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell free DNA (cfDNA) will be extracted from patients' plasma to detect for presence of somatic/germline mutation</measure>
    <time_frame>2 years</time_frame>
    <description>Extracted cfDNA will be subjected to ddPCR using designed probes for MET and TP53 mutations. Copies of cfDNA/1mL of plasma will be reported.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Squamous Cell Carcinoma of the Lung</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <arm_group>
    <arm_group_label>Lung and head and neck tumours</arm_group_label>
    <description>Age 18 years or older
Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung or head and neck region
No other active malignancy within the past 24 months
Refractory disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Patient blood was also required for extraction of cell free DNA (cfDNA) and genomic DNA
      (gDNA).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study intend to recruit a total of 80 patients over 2 years. Written informed consent
        will be requested from every patient prior to enrollment into the study. All eligibility
        criteria and consent form must be met before tumour DNA and plasma DNA from patients can be
        processed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older

          2. Histologic or cytologic confirmation of metastatic squamous cell carcinoma of the lung
             or head and neck region

          3. No other active malignancy within the past 24 months

          4. Refractory disease

        Exclusion Criteria:

          1. Patient with other active malignancy within the past 24 months

          2. Unable or unwilling to provide signed informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boon Cher Goh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boon Cher Goh</last_name>
    <phone>6779 5555</phone>
    <email>phcgbc@nus.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boon Cher Goh, MBBS, MRCP</last_name>
      <phone>65-6772-4617</phone>
      <email>Boon_Cher_Goh@nuhs.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <results_reference>
    <citation>Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA, Grandis JR. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.</citation>
    <PMID>21798893</PMID>
  </results_reference>
  <results_reference>
    <citation>Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Sep 27;489(7417):519-25. doi: 10.1038/nature11404. Epub 2012 Sep 9. Erratum in: Nature. 2012 Nov 8;491(7423):288. Rogers, Kristen [corrected to Rodgers, Kristen].</citation>
    <PMID>22960745</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 1, 2019</last_update_submitted>
  <last_update_submitted_qc>May 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mutations in MET and TP53</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

